Core Viewpoint - The company is planning to acquire controlling stakes in two firms, aiming to diversify into the semiconductor materials sector while facing performance pressures in its current pharmaceutical business [1][4]. Group 1: Transaction Overview - The company announced plans to acquire controlling rights in Zhangzhou Xipu Materials Technology Co., Ltd. and 40% of Zhejiang Beid Pharmaceutical Co., Ltd. through a combination of share issuance and cash payment [1][2]. - The acquisition of Beid Pharmaceutical will make it a wholly-owned subsidiary, as the company currently holds 60% of its shares [2]. - The transaction is classified as a major asset restructuring under regulatory guidelines, and the final valuations of the target companies are yet to be determined [1][3]. Group 2: Business Transition - The acquisition marks a strategic shift from the pharmaceutical sector to the semiconductor industry, which is expected to open new growth avenues for the company [4][5]. - The company has faced significant revenue declines, with a reported 8.33% drop in revenue to 144 million yuan and a 35.68% decrease in net profit in the first half of 2025 [4][5]. - The semiconductor materials market, particularly through Xipu Materials, represents a new business line that differs significantly from the company's existing pharmaceutical operations [5]. Group 3: Strategic Intent - The company has previously indicated a strategy of seeking external growth opportunities while stabilizing its current operations [5]. - The move to acquire Xipu Materials aligns with the company's history of restructuring, having transitioned from solar energy to pharmaceuticals and now to semiconductor materials [5].

Core Viewpoint - The company Sunflower is planning to acquire controlling stakes in two companies, Zhangzhou Xipu Materials Technology Co., Ltd. and 40% of Zhejiang Beid Pharmaceutical Co., Ltd., through a share issuance and/or cash payment, marking a significant strategic shift into the semiconductor materials sector from its current pharmaceutical focus [1][5]. Group 1: Transaction Details - The transaction is expected to constitute a major asset restructuring as defined by the regulations for listed companies [1][3]. - Sunflower currently holds a 60% stake in Beid Pharmaceutical, and the acquisition of the remaining 40% will make it a wholly-owned subsidiary [3]. - The acquisition of Xipu Materials will involve negotiations with Shanghai Xipu Technology Co., Ltd., which is the main counterparty in this transaction [3][5]. Group 2: Market Context and Performance - Sunflower's recent performance has shown a decline, with a reported revenue of 144 million yuan in the first half of 2025, down 8.33% year-on-year, and a net profit of 1.16 million yuan, down 35.68% [5][6]. - The company has faced challenges in its pharmaceutical business, particularly in the sales of certain products, prompting a strategic pivot to seek external growth opportunities [5][6]. Group 3: Strategic Implications - The acquisition of Xipu Materials represents a significant diversification into the semiconductor materials market, which is distinct from Sunflower's existing pharmaceutical operations [6]. - This move aligns with the company's previously stated strategy of seeking external growth while stabilizing its current business [6].

Core Viewpoint - Company is planning to acquire controlling stakes in two companies, aiming to diversify its business into the semiconductor sector while maintaining its core pharmaceutical operations [2][8]. Group 1: Acquisition Details - The company intends to acquire a controlling stake in Zhangzhou Xipu Materials Technology Co., Ltd., which specializes in electronic-grade materials for the semiconductor market, and 40% of Zhejiang Beid Pharmaceutical Co., Ltd., a core subsidiary [2][8]. - The acquisition is expected to constitute a significant asset restructuring, but will not change the actual control of the company [2][8]. - The company plans to raise supporting funds for this transaction [2]. Group 2: Financial Performance - On the last trading day before the announcement, the company's stock price rose by 11.96%, closing at 4.96 yuan per share [5]. - The company reported a revenue of 330 million yuan in 2024, a year-on-year decrease of 2.38%, and a net profit of 7.83 million yuan, down 64.01% [14]. - In the first half of 2025, the company generated 144 million yuan in revenue, a decline of 8.33%, with a net profit of 1.16 million yuan, down 35.68% [14]. Group 3: Strategic Intent - The company has a history of pursuing cross-industry expansions, with its current pharmaceutical business resulting from a previous acquisition in 2019 [11][12]. - The management has indicated a commitment to expanding market share and exploring external growth opportunities while ensuring the stability of existing operations [9].

无偿划转完成后，财政部不再持有中国信达股份，汇金公司直接持有中国信达221.37亿股内资股(约占 中国信达已发行股份总额的58%)，成为中国信达的控股股东。无偿划转完成后，中国信达仍为国有控 股金融机构。除上述所披露外，公司的其他间接及直接控股股东于无偿划转完成后维持不变。 格隆汇9月5日丨信达国际控股(00111.HK)公布，根据公司间接控股股东中国信达发出通知，无偿划转已 获国家金融监督管理总局及相关监管部门批覆同意。无偿划转已于2025年9月4日完成过户登记。 ...

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告之全部或任何部份內容 所產生或因依賴該等內容所引致之任何損失承擔任何責任。 （於百慕達註冊成立之有限公司） （股份代號 : 111） 2025 年 9 月 5 日 無償劃轉完成後，財政部不再持有中國信達股份， 匯 金 公 司 直接持有中國 信 達 22,137,239,084 股 內 資股 （ 約佔 中 國信 達 已發 行 股份 總額 的 58%），成 為中國信達 的 控 股 股 東 。 無 償 劃 轉 完 成 後 ， 中 國 信 達 仍 為 國 有 控 股 金 融 機 構 。 除 上 述 所 披 露 外 ， 本公司的 其 他 間 接 及 直 接 控 股 股 東 於 無償劃轉完成 後維 持 不變 。 本 公 告 由 本 公司 自願 發 出 。 本 公 司 股 東 及潛 在投 資 者 於 買 賣本 公司 股 份 時 ， 務須 審慎 行 事 。 承董 事 會命 信 達 國 際 控 股有 限公 司 執行 董 事兼 行 政總 裁 張尋遠 間接控股股東完成無償劃轉股份 茲提 述 信達 國 ...

Group 1 - The core point of the article is that 信达国际控股 (Sinda International Holdings) has conducted two asset sales in the public market on September 3, 2025 [1] Group 2 - The first asset sale involved the disposal of 山东和晟票据 (Shandong Hesheng Notes) with a principal amount of RMB 30 million (approximately HKD 33 million), sold for a total consideration of RMB 29.34 million (approximately HKD 32.28 million), excluding transaction costs [1] - The second asset sale involved the disposal of 昌邑渤潍债券 (Changyi Bowei Bonds) with the same principal amount of RMB 30 million (approximately HKD 33 million), sold for a total consideration of RMB 30.32 million (approximately HKD 33.35 million), also excluding transaction costs [1]

Core Viewpoint - The company has successfully sold two sets of bonds in the public market, indicating active management of its investment portfolio and potential liquidity generation [1] Group 1: Bond Sales - On September 3, 2025, the company sold Shandong Hesheng notes with a principal amount of RMB 30 million (approximately HKD 33 million) for a total consideration of about RMB 29.34 million (approximately HKD 32.28 million), excluding transaction costs [1] - On the same date, the company also sold Changyi Bowei bonds with a principal amount of RMB 30 million (approximately HKD 33 million) for a total consideration of about RMB 30.32 million (approximately HKD 33.35 million), excluding transaction costs [1]

Core Viewpoint - The company has successfully sold two sets of bonds in the public market, indicating active management of its investment portfolio and liquidity [1] Group 1: Bond Sales - On September 3, 2025, the company sold Shandong Hesheng notes with a principal amount of RMB 30 million for approximately RMB 29.34 million, excluding transaction costs [1] - On the same date, the company also sold Changyi Bowei bonds with a principal amount of RMB 30 million for approximately RMB 30.32 million, excluding transaction costs [1]

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告之內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就因本公告之全部或任何部份內容所產生或因依賴該等內容所引致之 任 何 損 失 承 擔 任 何 責 任。 （於百慕達註冊成立之有限公 司） （股份代 號：111） 須予披露交易－ 出售票據及債券 出售事項 – 1 – 山東和晟票據出售事項 於 2025 年9 月 3 日，本 公 司 已 於 公 開 市 場 出 售 本 金 總 額 為 人 民 幣3 0 百 萬 元（相 當 於 約 3 3 百 萬 港 元）之 山 東 和 晟 票 據，總 代 價 為 約 人 民 幣 29.34 百 萬 元（相 當 於 約32.28百 萬 港 元），不 包 括 交 易 成 本。 昌邑渤濰債券出售事項 於 2025 年9 月 3 日，本 公 司 已 於 公 開 市 場 出 售 本 金 金 額 為 人 民 幣3 0 百 萬 元（相 當 於 約 3 3 百 萬 港 元）之 昌 邑 渤 濰 債 券，代 價 為 約 人 民 幣 30.32 百 萬 元（相 當 於 約33 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 信達國際控股有限公司 呈交日期: 2025年9月2日 本月底法定/註冊股本總額： HKD 100,000,000 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00111 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 641,205,600 | | | | 641,205,600 | | 增加 / 減少 (-) | | | | | | | | | 本月底結存 | | | 641,205,600 | | 0 | | 641,205,60 ...